uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 12,000 Shares

uniQure N.V. (NASDAQ:QURE) CFO Christian Klemt sold 12,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $108,720.00. Following the completion of the sale, the chief financial officer directly owned 226,581 shares in the company, valued at approximately $2,052,823.86. The trade was a 5.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Christian Klemt also recently made the following trade(s):

• On Wednesday, February 25th, Christian Klemt sold 6,217 shares of uniQure stock. The shares were sold at an average price of $23.86, for a total transaction of $148,337.62.

uniQure Price Performance

Shares of NASDAQ QURE traded up $3.62 during mid-day trading on Friday, hitting $14.27. 16,602,429 shares of the stock were exchanged, compared to its average volume of 3,442,688. uniQure N.V. has a twelve month low of $7.76 and a twelve month high of $71.50. The stock’s fifty day simple moving average is $22.25 and its two-hundred day simple moving average is $29.44. The company has a debt-to-equity ratio of 0.25, a quick ratio of 7.12 and a current ratio of 10.43. The company has a market cap of $892.30 million, a P/E ratio of -4.14 and a beta of 0.73.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. As a group, analysts forecast that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. TD Cowen restated a “buy” rating on shares of uniQure in a research report on Tuesday. Mizuho reissued a “neutral” rating and issued a $12.00 price target (down from $33.00) on shares of uniQure in a report on Tuesday. William Blair reaffirmed a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Sanford C. Bernstein cut uniQure to a “market perform” rating in a research note on Tuesday. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $15.00 price target (down from $60.00) on shares of uniQure in a research note on Tuesday. Seven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $34.33.

Institutional Investors Weigh In On uniQure

Large investors have recently bought and sold shares of the company. Private Trust Co. NA acquired a new position in shares of uniQure in the 3rd quarter valued at $28,000. Torren Management LLC bought a new position in shares of uniQure during the 4th quarter valued at about $28,000. Jones Financial Companies Lllp grew its position in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares during the period. IFP Advisors Inc acquired a new stake in uniQure during the 4th quarter worth approximately $48,000. Finally, Smartleaf Asset Management LLC bought a new position in uniQure in the fourth quarter valued at approximately $48,000. Institutional investors own 78.83% of the company’s stock.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Mizuho issued a neutral rating on QURE, keeping some analyst coverage tepid rather than bullish. Read More.
• Negative Sentiment: A senior FDA official publicly called uniQure’s Huntington’s disease therapy unsuccessful and defended the agency’s call for a new randomized, placebo‑controlled study — a move that raises the likelihood of delays and additional trials before any BLA. Read More.
• Negative Sentiment: Broad media coverage amplifies regulatory risk: multiple outlets (WSJ, CNBC, FierceBiotech, BioSpace) report public rebukes from FDA/HHS and intensifying back‑and‑forth with uniQure — increasing reputational and approval uncertainty. Read More.
• Negative Sentiment: Numerous class‑action and shareholder‑lawsuit notices filed and circulated by law firms (lead‑plaintiff deadline April 13, 2026) — these raise potential legal liability, management distraction, and ongoing downward pressure on the share price. Read More.
• Negative Sentiment: Analyst actions have turned negative: Chardan cut its price target and other outlets report pessimistic forecasts (Goldman Sachs coverage noted), contributing to recent downgrades and reduced sell‑side enthusiasm. Read More.
• Negative Sentiment: Multiple insiders (including the CEO and CFO) sold shares on March 4 at ~$9.06 — the CEO, CFO and other insiders reduced holdings by low single‑digit to ~5% amounts. Insider selling can be perceived negatively by the market even though insiders still hold large positions. Read More.
• Negative Sentiment: Short‑term price shock: Zacks and other outlets report the stock plunged ~32% in a week after the FDA said AMT‑130 Phase I/II data are insufficient as primary evidence for a marketing application — underscores how quickly regulatory comments can swing valuation. Read More.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.